For long-term secondary prevention of MI, the use of P2Y12 monotherapy has a borderline advantage over aspirin alone and does not affect bleeding, according to a meta-analysis of nine randomized ...

Please provide your email address to receive an email when new articles are posted on . Valgimigli is deputy chief of interventional cardiology at Cardiocentro Ticino Institute, Lugano, Switzerland.

In patients with atrial fibrillation undergoing PCI, antithrombotic regimens involving a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) should be avoided, whereas use of a non-VKA ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation ...

BARCELONA -- Patients with documented coronary artery disease (CAD) saw cardiovascular benefits with P2Y12-inhibitor monotherapy when compared with aspirin alone, according to the PANTHER ...

Background: The initial results for CURRENT-OASIS 7 were presented at the European Society of Cardiology Congress 2009 in Barcelona. To date, final analyses of the study have not been published in a ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

Idorsia Ltd (IDIA.SW) today announced that Phase 2 clinical studies with selatogrel (recommended INN for ACT-246475), Idorsia`s P2Y12 receptor antagonist, in patients with stable coronary artery ...

What The Study Did: In this randomized clinical trial with 562 noncritically ill patients hospitalized for COVID-19, the use of a P2Y12 inhibitor combined with a therapeutic dose of heparin didn’t ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...